An Open Label, 3-arm, Randomised Phase II Study to Compare the Safety and Efficacy of
Ponatinib in Combination With Either Chemotherapy or Blinatumomab With Imatinib Plus
Chemotherapy as Front-line Therapy for Patients Aged 55 Years and Over With Philadelphia
Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)